Intrinsic Imaging, an FDA audited, ISO 9001, ISO 13485 and ISO 22301:2012 certified medical imaging core lab specializing in providing imaging core lab services for clinical trials, announced today that it has been awarded a global clinical trial to assess patients with hepatocellular carcinomas (HCC).

When it meets in Baltimore on April 30 to weigh recommending Medicare coverage of low-dose CT lung-cancer screening, the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) will consider public comments from 16 speakers including four radiologists, a radiation oncologist and a radiation physicist.  

Almost 45 years after publication in JAMA of the results of the first randomized controlled trial of screening mammography in the U.S. by Shapiro, Strax and Venet in 1971, the war continues to rage.

Bring thick skin and wide support when assuming a leadership role in a public-health initiative

Three years ago, the National Lung Screening Trial (NLST) reported a 20% reduction in lung-cancer mortality with annual low-dose CT (LDCT) screening.

The annual mid-March report to Congress of the Medicare Payment Advisory Commission (MedPAC) often is a good predictor of things to come, many of which have rocked radiology’s boat since 2005.

The Hospital Consumer Assessment of Healthcare Providers and Systems, or HCAHPS, survey—now driving a portion of hospital revenue—touches radiology only tangentially, so it would be convenient to leave the patient experience to someone else.

The first baby boomers are beginning to retire, signaling the beginning of unprecedented demand on the health-care system. How will radiology be affected?